Advertisement

Topics

PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan

09:00 EDT 21 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Alliance to drive greater efficiencies across clinical trials in oncology and hematology PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer ...

Other Sources for this Article

PAREXEL Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com
or
Investors:
Ronald Aldridge
Tel.: +1 781-434-4753
Email: Ron.Aldridge@PAREXEL.com
or
Osaka International Cancer Institute Contact:
Hiroshi Yamasaki, Public Relations
Tel.: +81 6-6945-1181
Email: yamasakih@opho.jp

NEXT ARTICLE

More From BioPortfolio on "PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...